People with HIV have a virus that spreads in their body and damages the immune system, making it easier for them to get very sick from other infections. The medicine contained in Sunlenca works ...

Lenacapavir 463.5mg/1.5mL (309mg/mL); soln for SC inj; preservative-free. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid ...

The U.S. Food and Drug Administration has approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with HIV-1 whose HIV infection cannot be successfully ...

There is a new long-acting drug for people with highly resistant HIV who have, until now, had limited medication options. On December 22, the federal Food and Drug Administration approved Gilead ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has approved Sunlenca, an injectable therapy to suppress HIV for patients who suffered drug ...

FILE PHOTO: The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California (Reuters) - The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's ...

CAPE TOWN, South Africa (AP) — Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to study results published Wednesday. There were no infections ...

Sunlenca from Gilead Sciences is the kind of product you notice even before you see the label, a compact carton with a slim glass vial that hospital pharmacists in Boston now keep in a separate fridge ...

The Food and Drug Administration has approved Sunlenca, an injectable therapy to suppress HIV for patients who suffered drug resistance to other regimens. Experts say the new injectable, which works ...

CAPE TOWN, South Africa — Twice-yearly shots used to treat AIDS were 100 percent effective in preventing new infections in women, according to study results published July 24. There were no infections ...

(Reuters) -The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than ...